Home/Pipeline/LYT-310

LYT-310

Epilepsy

PreclinicalActive

Key Facts

Indication

Epilepsy

Phase

Preclinical

Status

Active

Company

PureTech Health

About PureTech Health

PureTech Health is a Boston-based biotech studio that creates and funds separate companies around innovative scientific discoveries, de-risking development and capturing value through equity and royalties. Its model has proven exceptionally successful, boasting a 6x higher clinical success rate than the industry average and delivering three FDA-approved therapies. The company's strategy leverages a deep network of academic collaborators and seasoned leadership to build a diversified portfolio across immunology, neurology, and gastroenterology.

View full company profile

Therapeutic Areas

Immunology Neurology Gastroenterology Psychiatry Oncology Metabolic Disease

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active